Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases
Authors:
- 1 April 2019
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 14 (4) , 683-690
Abstract
No abstract availableKeywords
Funding Information
- Genentech
- Novartis
- National Cancer Institute (R01CA164273)
- Roche
- Massachusetts General Hospital
- Clovis Oncology
- Pfizer
This publication has 19 references indexed in Scilit:
- Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung CancersThe Oncologist, 2018
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialThe Lancet Oncology, 2017
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialJournal of Clinical Oncology, 2017
- Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trialThe Lancet Oncology, 2016
- Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global StudyJournal of Clinical Oncology, 2016
- Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK -positive NSCLC: Implications for disease assessment and managementLung Cancer, 2015
- Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastasesCancer Chemotherapy and Pharmacology, 2014
- Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 studyThe Lancet Oncology, 2014